Literature DB >> 19820689

Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system: a study of 77 cases.

Kaiyong Mei1, Aijun Liu, Robert W Allan, Peng Wang, Zhaoli Lane, Ty W Abel, Lixin Wei, Hong Cheng, Shuangping Guo, Yan Peng, Dinesh Rakheja, Min Wang, Joe Ma, Maria M Rodriguez, Jianping Li, Dengfeng Cao.   

Abstract

Primary germ cell tumors of the central nervous system (CNS) sometimes pose diagnostic difficulty. In this study we analyzed the diagnostic utility of a novel marker, SALL4, in 77 such tumors (59 pure and 18 mixed) consisting of the following tumors/tumor components: 49 germinomas, 7 embryonal carcinomas, 27 yolk sac tumors, 3 choriocarcinomas, and 14 teratomas. We also stained SALL4 in 99 primary non-germ cell tumors to test SALL4 specificity. We compared SALL4 with OCT4 in all germ cell tumors and compared SALL4 with alpha-fetoprotein and glypican-3 in all yolk sac tumors. The staining was semiquantitatively scored as 0 (no staining), 1+ (<or=30%), 2+(31-60%), 3+ (61-90%), and 4+ (>90%). Strong SALL4 staining was observed in all 49 germinomas (4+ in 48, 3+ in 1), 7 embryonal carcinomas (all 4+), and 27 yolk sac tumors (1+ in 1, 2+ in 2, 3+ in 7, 4+ in 17). SALL4 staining, 1+ weak to focally strong, was observed in 2 of 3 choriocarcinomas (in mononucleated trophoblasts) and in 9 of 14 teratomas (in primitive neuroepithelium and teratomatous glands). All germinomas and embryonal carcinomas showed strong OCT4 staining (4+ in all except 1 germinoma with 3+), whereas other germ cell tumors were negative. Out of 27 yolk sac tumors, 26 showed positive alpha-fetoprotein staining (1+ in 9, 2+ in 7, 3+ in 5, and 4+ in 5). All yolk sac tumors showed positive glypican-3 staining (1+ in 6, 2+ in 6, 3+ in 7, and 4+ in 8). The mean percentage of yolk sac tumor cells stained was 84% with SALL4, 45% with alpha-fetoprotein, and 63% with glypican-3 (P<0.01). No non-germ cell tumors showed SALL4 staining. Our results indicate that SALL4 is a novel sensitive diagnostic marker for primary germ cell tumors of the CNS with high specificity. SALL4 is a more sensitive marker than alpha-fetoprotein and glypican-3 for yolk sac tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19820689     DOI: 10.1038/modpathol.2009.148

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  21 in total

1.  Teratoma of the Sellar Region: a Case Report.

Authors:  Wolfgang Saeger; Azadeh Ebrahimi; Rudi Beschorner; Hildegard Spital; Jürgen Honegger; Waldemar Wilczak
Journal:  Endocr Pathol       Date:  2017-12       Impact factor: 3.943

2.  Mixed malignant germ cell tumour of third ventricle with hydrocephalus: a rare case with recurrence.

Authors:  Manjari Kishore; Vidya Monappa; Lakshmi Rao; Ranjini Kudva
Journal:  J Clin Diagn Res       Date:  2014-11-20

3.  HESRG: a novel biomarker for intracranial germinoma and embryonal carcinoma.

Authors:  Siyi Wanggou; Xingjun Jiang; Qiaoyu Li; Lihua Zhang; Dingyang Liu; Guifei Li; Xiangling Feng; Weidong Liu; Bin Zhu; Wei Huang; Jia Shi; Xianrui Yuan; Caiping Ren
Journal:  J Neurooncol       Date:  2011-08-23       Impact factor: 4.130

Review 4.  The role of stem cell factor SALL4 in leukemogenesis.

Authors:  Chong Gao; Nikki R Kong; Li Chai
Journal:  Crit Rev Oncog       Date:  2011

Review 5.  SALL4, the missing link between stem cells, development and cancer.

Authors:  Hiro Tatetsu; Nikki R Kong; Gao Chong; Giovanni Amabile; Daniel G Tenen; Li Chai
Journal:  Gene       Date:  2016-02-16       Impact factor: 3.688

6.  Immunoexpression of SALL4 in Wilms tumors and developing kidney.

Authors:  Jeremy Deisch; Jack Raisanen; Dinesh Rakheja
Journal:  Pathol Oncol Res       Date:  2011-01-22       Impact factor: 3.201

7.  SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases.

Authors:  Ta-Chiang Liu; Neeta Vachharajani; William C Chapman; Elizabeth M Brunt
Journal:  Am J Surg Pathol       Date:  2014-07       Impact factor: 6.394

8.  Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: mechanism, function, and implication for a potential novel therapeutic target.

Authors:  Shikiko Ueno; Jiayun Lu; Jie He; Ailing Li; Xiaoxian Zhang; Jerome Ritz; Leslie E Silberstein; Li Chai
Journal:  Exp Hematol       Date:  2014-01-23       Impact factor: 3.084

9.  Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex.

Authors:  Chong Gao; Todor Dimitrov; Kol Jia Yong; Hiro Tatetsu; Ha-won Jeong; Hongbo R Luo; James E Bradner; Daniel G Tenen; Li Chai
Journal:  Blood       Date:  2013-01-03       Impact factor: 22.113

10.  The zinc-finger transcription factor SALL4 is frequently expressed in human cancers: association with clinical outcome in squamous cell carcinoma but not in adenocarcinoma of the esophagus.

Authors:  Ergin Kilic; Pierre Tennstedt; Anica Högner; Patrick Lebok; Guido Sauter; Carsten Bokemeyer; Jakob R Izbicki; Waldemar Wilczak
Journal:  Virchows Arch       Date:  2016-01-27       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.